N- (4- (5- bromo- 2- pyrimidinyloxy)- 3- chlorophenyl)- N'- (2- nitrobenzoyl)urea

12/01/1990 - "We previously reported HO-221 showed significant antitumor activities against various experimental tumor models, and was especially effective against the solid tumor. "
10/01/1991 - "This study was designed to evaluate the antitumor effect of HO-221 and to establish the optimum regimen, using seven human gastrointestinal and breast cancers xenografted in nude mice. "
10/01/1991 - "Antitumor effect of HO-221, a derivative of benzoylphenylurea, has been previously studied against seven human cancer xenografts in nude mice established and maintained in our laboratory. "
10/01/1991 - "HO-221, a derivative of benzoylphenylurea, is a newly developed anticancer drug which was found to show an excellent antitumor effect against transplantable murine tumors by the novel mechanism of action. "
10/01/1991 - "[Antitumor activity of HO-221, a derivative of benzoylphenylurea against human cancer xenografts in nude mice]."

01/01/1995 - "The in vitro cytotoxic strength of HO-221 was investigated, as measured by IC50 values, compared with those of other drugs with different action mechanisms, using Chinese hamster lung (CHL) cells, mouse leukemia L1210 cells and human promyelocytic leukemia HL-60 cells. "
01/01/1991 - "Furthermore, the effect of HO-221 on drug-resistant tumors was examined using murine leukemias L1210 and P388. "
02/01/1991 - "In this study, we examined the cross-resistance of HO-221 to various antitumor agents using sublines of mouse leukemia. "
02/01/1991 - "[Cross-resistance of HO-221 and various antitumor agents in sublines of mouse leukemia]."
02/01/1991 - "These antitumor agents were also effective in P 388 leukemia resistant to HO-221 (P 388/HO-221). "

01/01/1995 - "The in vitro cytotoxic strength of HO-221 was investigated, as measured by IC50 values, compared with those of other drugs with different action mechanisms, using Chinese hamster lung (CHL) cells, mouse leukemia L1210 cells and human promyelocytic leukemia HL-60 cells. "
04/01/1991 - "[Combined effect of HO-221 with various antitumor agents against L 1210 leukemia]."
01/01/1991 - "HO-221 showed activity against LX-1 lung and Co-1 gastrointestinal tumor and was also effective against advanced-stage L1210 leukemia and Lewis lung carcinoma. "
04/01/1991 - "Combined effect of N-[4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl]-N'-(2-nitrobenzoyl ) urea, HO-221, with various antitumor agents was studied using L 1210 leukemia in vivo and in vitro. "

12/01/1990 - "Against Lewis lung carcinoma, HO-221 showed both the increase of life span and the tumor growth inhibition. "
01/01/1991 - "HO-221 showed activity against LX-1 lung and Co-1 gastrointestinal tumor and was also effective against advanced-stage L1210 leukemia and Lewis lung carcinoma. "

10/01/1991 - "While HO-221 was not effective to a gastric cancer line, H-81, which was most susceptible to the variety of existing anticancer agents, but effective to another gastric cancer line, H-111, which was relatively resistant to conventional cytocidal agents. "